Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivesto AB ( (SE:VIVE) ) has issued an announcement.
Vivesto AB announced a live-streamed business update scheduled for November 24, highlighting recent advancements in its oncology-focused development pipeline. The company reported positive interim results from a clinical pilot study of Paccal Vet in dogs with splenic hemangiosarcoma, showing longer survival rates, and promising preclinical results for Cantrixil in treating acute myeloid leukemia. These developments underscore Vivesto’s commitment to addressing unmet medical needs in cancer treatment, with potential new therapeutic options for both veterinary and human applications.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on offering new treatment options for hard-to-treat cancers with significant medical needs and market potential. The company’s project portfolio includes Cantrixil, aimed at blood cancer, and the veterinary oncology program Paccal Vet, which is being evaluated in clinical trials for dogs with splenic hemangiosarcoma and in a dose-finding study in cats with solid tumors.
Average Trading Volume: 540,297
Technical Sentiment Signal: Sell
Current Market Cap: SEK127.8M
See more insights into VIVE stock on TipRanks’ Stock Analysis page.